The number needed to treat for the composite anemia outcome was estimated at 55; that is, 1 additional composite anemia outcome may be prevented among every 55 patients with T2D and CKD stages 1 to 3 who newly receive SGLT2 inhibitors for a 1-year treatment compared with GLP-1 RA use. This evidence concerns the gene SLC5A2 and chronic kidney disease.